Bibliography
- Chuang-Stein C, Mohberg N, Sinkula M. Three measures for simultaneously evaluating benefit and risks using categorical data from clinical trials. Stat Med 1991;10:1349-59
- Tubert-Bitter P, Bloch DA, Raynauld J. Comparing the bivariate effects of toxicity and efficacy of treatments. Stat Med 1995;14:1129-41
- Schulzer M, Mancini G. ‘Unqualified success’ and ‘unmitigated failure’: number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. Int J Epidemiol 1996;25:704-12
- Shakespeare T, Gebski V, Veness M, Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk:benefit contours. Lancet 2001;357:1349-53
- Holden W. Benefit-risk analysis. Drug Saf 2003;26:853-62
- Sutton A, Cooper N, Abrams K, A bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty. J Clin Epidemiol 2005;58:26-40
- Boada JN, Boada C, García-Sáiz M, Net Efficacy Adjusted for Risk (NEAR): a simple procedure for measuring risk: benefit balance. PLoS ONE 2008;3(10):e3580. Doi:10.1371/journal.pone.0003580
- Webster J, Piscitelli G, Polli A, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. NEJM 1994;331:904-9
- Josan K, Majumdar S, McAlister D. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 2008;178:576-84
- Friedman M, Woodcock J, Lumpkin M, The safety of newly approved medicines. JAMA 1999;218:1728-34
- Lexchin J. Drug withdrawals from the canadian market for safety reasons, 1963-2004. CMAJ 2005;172:765-7
- De Backer T, Vander-Stichele R, Van Bortel L. Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication. Drug Saf 2009;32:283-91
- Walker S, McAuslane N, Liberti L, Measuring benefit and balancing risk: strategies for the benefit–risk assessment of new medicines in a risk-adverse environment. Clin Pharmacol Ther 2009;85:241-6
- Dieppe P, Bartlett Ch, Davey P, Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs. BMJ 2004;329:31-4
- Korn D, Ehringhaus S. Principles for strengthening the integrity of clinical research. PLoS Clin Trials 2006;1(1):e1. DOI: 10.1371/journal.pctr.0010001
- Smith R, Roberts I. Patient safety requires a new way to publish clinical trials. PLoS Clin Trials 2006;1(1):e6. DOI:10.1371/journal.pctr.0010006
- Wysowsky D, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Int Med 2005;165:1363-69
- European Medicines Agency. Note for guidance on clinical safety data management: definitions and standards for expedited reporting (CPMP/ICH/377/95)
- Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977;21:247-54